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Abstract
Background: There is recent evidence that glucose delivered to the distal small intestine (SI) may stimulate
the ileal brake and inhibit appetite. High polyphenolic grape extract (PGE) has been shown to inhibit
α-amylase and α-glucosidase activity, two key enzymes required for starch digestion, in vitro. It is
hypothesised to slow digestion and absorption of starch in the proximal SI such that glucose may be
delivered distally into the ileum and suppress appetite. This study investigated the safety and efficacy of a
PGE supplement, delivered within a capsule and consumed with a high-starch breakfast, on appetite ratings
and ad libitum energy intake (EI) at a subsequent lunch meal.
Methods: Twenty healthy, non-obese (BMI 18–28 kg/m2) male volunteers participated in a randomised,
double blind, placebo controlled, three arm, cross-over study. Participants were administered (i) low dose
PGE500 (500 mg), (ii) high dose PGE1500 (1500 mg), and (iii) matched placebo with a 2MJ high-starch
breakfast (white bread); followed 3 h later by a single item buffet-style lunch meal (pasta and meat
sauce). Outcome variables were feelings of hunger, fullness, prospective thoughts of food (TOF) and
satisfaction assessed using visual analogue scales (VAS); and ad lib energy and macronutrient intake
at the lunch meal.
Results: There was no detectable effect of PGE500 or PGE1500 compared with placebo (all, time*supplement
interaction, P > 0.05) on VAS-assessed hunger, fullness, TOF or satisfaction. There was also no evidence that
PGE significantly altered ad lib energy or macronutrient intake at the lunch meal relative to placebo (P > 0.05).
EI following PGE500 was +164 kJ higher than placebo (+5.3 %, P > 0.05); and EI following PGE1500was −51 kJ
lower than placebo (−1.7 %, P > 0.05).
Conclusions: Whilst well tolerated, there was no evidence that encapsulated low dose PGE500 or high dose
PGE1500 consumed with a high starch breakfast meal altered postprandial hunger, fullness, TOF or satisfaction
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Background
Weight gain and obesity have emerged as a significant
problem currently affecting global public health. The
current therapeutic options for the overweight and obese
are limited as most lack efficacy or are associated with
adverse side-effects [1–3]. Satiety plays an important
role in the maintenance of body weight and prevention
of obesity as it allows the regulation of food intake on a
meal to meal basis [4]. Amongst the numerous interact-
ing mechanisms contributing to the regulation of satiety,
enteroendocrine signals originating from the gastrointes-
tinal (GI) tract are hypothesised to play an important
role [5–7].
One hypothesis is focused on signals that may arise
from the ileum, the most distal part of the small intes-
tine (SI), or hind gut and there has been interest in diet-
ary available CHO as a potential trigger for satiety
signals arising from the ileum. There is a growing body
of evidence from both animal and clinical studies that
infusing glucose directly into the ileum can modify a
range of GI activities, and that in turn this may put a
brake on food intake [8]. However, achieving this effect
with food is extremely challenging as the digestion and
absorption of CHO occurs mainly in the stomach,
duodenum and jejunum of the proximal SI, or fore gut,
resulting in minimal delivery of monosaccharide glucose
into the ileum [8–10]. The initial step in the enzymatic
digestion of starch involves cleavage of the glucose-
glucose α-(1, 4) glycosidic bond by α-amylase to
produce shorter dextrin chains and glucose-glucose
disaccharides (such as maltose and isomaltose). These
products are then further hydrolysed into individual
glucose units by a set of brush border enzymes
collectively called α-glucosidases. Only these mono-
saccharide forms of CHO are then taken up by gut
epithelial cells using specific transporters, sodium/glu-
cose cotransporter 1 (sGLT1) and glucose transporter
2 (GLUT2) [11, 12].
Polyphenols are a structural class of plant-origin
compounds characterized by the presence of large multi-
ples of phenol structural units. The number and charac-
teristics of these phenol structures underlie the unique
physical, chemical, and biological (metabolic, toxic,
therapeutic) properties of particular members of the
class. The health benefits of polyphenols have been
extensively studied and implicated as protective agents
in a number of chronic diseases, including cardiovascu-
lar disease (CVD), diabetes and cancer [13–15]. Re-
cently, a variety of polyphenols have been shown to
exert biological effects in CHO metabolism by inhibiting
the activity of α-amylase and α-glucosidase, two key
enzymes required for starch digestion [14, 16–20]. On
this basis, it is plausible that plants rich in polyphenols,
when given with a high starch-based meal, may be able
to induce CHO (glucose) malabsorption in the fore gut.
This mechanism may allow transit of available CHO
further down the GI tract, possibly as far as the hind
gut, which in turn may result in the activation of satiety
responses. A similar mechanism is utilized by the
pharmaceutical industry in diabetic therapies such as
acarbose or miglitol, which block CHO uptake in the
fore gut to ameliorate glycaemia, and where in turn
there is some evidence of appetite suppression [21, 22].
Grapes contain high concentrations of bioactive poly-
phenols [23]. Notably, recent in vitro studies have shown
polyphenolic grape extracts (PGE), including grape seed
extract (GSE), to be associated with significant inhibition
of activity of α-amylase and α-glucosidase with the
potential to prevent the breakdown of starch into its
glucose components, blocking a step that is required for
the absorption of dietary available CHO [23–25]. The
objective of the present study was to test whether PGE,
hypothesised to induce post-meal CHO malabsorption
in the fore gut when consumed with a starch-rich food,
would enhance satiety and reduce food intake at a later
meal. Specifically, it aimed to compare the effects of
low-dose (500 mg) and high-dose (1500 mg) PGE
protected from gastric acid by delivery within a capsule
and consumed with a standardised high-starch breakfast
meal, on postprandial appetite and food intake.
Methods
Participants
Twenty healthy men (BMI 18–28 kg/m2) aged between
18 and 60 years were recruited in Auckland, New
Zealand during January and February 2014, through pos-
ter and electronic advertisement. Participants were non-
smokers, had no history of CVD, diabetes, or any other
significant metabolic, endocrine or GI disease, and were
not taking any medications that may have had any effect
on appetite or weight regulation throughout the trial
period. Other exclusion criteria included participation in
an active diet program or loss/gain of >5 kg body weight
within the last 6 months. Hypersensitivities or allergies
to any foods or ingredients included in the study, as well
as dislike and/or unwillingness to consume items listed
as study foods (breakfast and lunch meals), unwilling/
unable to comply with study protocol, or current partici-
pation in another clinical intervention trial were also
exclusions. Participants were ascertained healthy by self-
report during a screening visit. Human ethics consent
was obtained from the New Zealand Health and Disabil-
ity Ethics Committee (HDEC, Reference Number: 13/
NTA/225). The trial was registered with the Australia
New Zealand Clinical Trials Registry (ANZCTR), clinical
trial registration number ACTRN12614000041651, and
conducted at the Human Nutrition Unit (HNU), Univer-
sity of Auckland, New Zealand. Prior to registration for
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the trial, all participants provided written informed con-
sent and were instructed that they were able to withdraw
from the trial at any time.
Study design, supplements, and protocol
This was a randomised, placebo controlled, double
blind, three condition, cross-over study. Two doses of
dried PGE (500 mg, 1500 mg) and a matched placebo
(magnesium stearate, Mg(C18H35O2)2) were protected
from gastric acid by encapsulation, using size ‘0’
capsules (Capsugel®, Morristown, USA, see Table 1),
and administered as part of a standardised 2MJ high-
starch, low-polyphenol breakfast (185 g white bread,
Tip Top Super Soft®, containing 83 g polysaccharide
starch). A commercial source of PGE was used in this
trial (New Zealand Extracts Ltd, Marlborough, New
Zealand) which was an extract from red and white
grape seeds and skins extracted using a proprietary
water-based method. Total polyphenolic content was
measured using HPLC according to Association of
Official Analytical Chemists (AOAC) 15th Edition,
952.03 methods standard [26]. Each capsule contained
353 mg polyphenolics per 500 mg PGE, hence total
polyphenol content was ~70 % by weight. The predomin-
ant phenolic components in the extract identified by
HPLC were oligomeric proanthocyanidins (OPC, which
were >40 % of total phenolics), epicatechin and epicate-
chin gallate. NZ Extracts Ltd also undertook blinding of
the capsules, correct allocation of which was subsequently
confirmed by the research team upon completion of the
trial using capsules taken from the original source. The
intervention arms were: standardised breakfast plus low
dose PGE (PGE500: 1 PGE capsule plus 2 placebo
capsules); standardised breakfast plus high dose PGE
(PGE1500: 3 PGEcapsules); and standardised breakfast plus
placebo (Placebo: 3 placebo capsules); hence 3 capsules
were administered on each occasion to ensure the blind
was maintained. The trial was not unblinded until
completion of both the intervention and statistical
analyses. Each study visit was separated by a washout
period of at least 3 days where participants were free to
resume their usual diet and exercise patterns.
The trial was conducted according to the standard
methodologies of Blundell et al. [27] for the assessment
of postprandial appetite response and subsequent eating
behaviour, using a preload design. On the morning of
each study day, participants arrived at the HNU at
0830 h after an overnight fast and baseline subjective
appetite ratings were measured (t = 0). The standardised
high starch breakfast was served at 0900 h with the test
capsules and 250 mL of water. Participants were asked
to consume the meal in full, but at their own pace,
within 15 min. No further foods were allowed through-
out the morning and the participants remained within
the HNU until an ad libitum lunch was served at 1200 h
(180 min later, t = 180). Appetite ratings were measured
throughout the morning and for 2 h after completion of
the lunch. The ad lib lunch was served in individual
sensory booths, no distractions were allowed during the
30 min lunch period, and participants were instructed
to eat until they felt comfortably full. Participants
remained at the HNU throughout each study day and
were allowed to read, use laptop computers or under-
take other similar sedentary activities but were not
allowed to sleep.
For the measurement of energy and macronutrient
intake, foods were weighed before and after the lunch
meal. Throughout the day participants rated hunger,
fullness and other appetite-related sensations, including
satisfaction, current thoughts of food (TOF), thirst and
nausea. Palatability of the breakfast and ad lib lunch was
assessed following each respective meal. The daily proto-
col of the study is shown in Fig. 1.
Appetite ratings
Subjective measures of hunger, fullness, satisfaction,
TOF and nausea were the primary outcome in this trial,
and were measured using validated visual analogue
scales (VAS) according to the standard methodology of
Blundell et al. [27] and previously described by our
research group [28–30]. The trial was powered to detect
a change in VAS of 10 % relative to placebo as statisti-
cally significant. The following questions were asked:
“How hungry do you feel?/How full do you feel?/How











PGE500 1 PGE + 2 placebo 500 500 353 >40 %
PGE1500 3 PGE 500 1500 1059 >40 %
Placebo 3 placebo 0 0 0 0
The PGE supplement was a commercial extract from red and white grape seeds and skins, extracted using a proprietary water-based method and provided by
New Zealand Extracts Ltd (Marlborough, New Zealand). The predominant phenolic component in the extract was oligomeric proanthocyanidin (OPC), comprising
>40 % of total polyphenols. Total polyphenol content was measured using Association of Official Analytical Chemists (AOAC) 15th Edition 952.03 standard
methods. Placebo comprised magnesium stearate matched by capsule number, capsule weight and capsule size (size ‘0’) to the PGE treatments
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satisfied do you feel?/How much do you think you can
eat now/How nauseated do you feel?” anchored on the
left by “I am not hungry at all/I am not full at all/I am
completely empty/nothing at all/not nauseas at all” and
“I am as hungry as I have ever been/I am totally full/I
cannot eat another bite/a large amount/very nauseated”
on the right. Participants marked their responses by
placing a vertical line across the 100-mm scale according
to their subjective feelings. Moreover, a set of scales
rating how thirsty, energetic and relaxed the participants
felt were included as a distraction from the main
outcome. VAS were measured at 15, 30, 45, 60, 90, 120,
150, 180 (ad lib lunch), 210, 240, 270 and 330 min after
the breakfast was served. Immediately after the breakfast
and the ad lib lunch meal participants also rated the
pleasantness, visual appeal, smell, taste, aftertaste and
overall palatability on separate 100-mm VAS.
Standardised breakfast and ad libitum lunch
The standardised breakfast comprised 185 g of sliced
white bread, as shown in Table 2. The ad lib outcome
meal was a lunch which comprised a restricted item
savoury buffet consisting of beef and tomato sauce,
boiled pasta spirals, and bottled water. EI at the outcome
meal was a secondary outcome, with sample size
adequate to detect a change of ~0.5MJ as statistically
significant. In an attempt to avoid over-consumption the
variety of meal items offered was limited, each item
served in moderate excess with the intent that partici-
pants would not consume the entirety of either single
item. We have previously demonstrated that this proto-
col is sensitive to changes made in a prior test preload
[31]. Prior to the study, it had been established with each
participant that the items provided in the ad lib lunch
were acceptable as meal choices. Participants were
Fig. 1 Daily protocol. Participants were given a standardised 2MJ high-starch breakfast plus PGE treatment or placebo capsules at 9am, then of-
fered a lunch meal 3 hours later which they were encouraged to eat ad libitum until until they felt comfortably full. Visual analogue scores (VAS)
were assessed throughout the day. Participants were restricted to the research clinic and allowed to consume only foods and beverages provided
within the study. PGE, polyphenolic grape extract
Table 2 Composition of the preload breakfast and ad libitum outcome lunch meal
Weight (g) Energy (kJ) CHO (g) CHO (%) Fat (g) Fat (%) Protein (g) Protein (%)
Breakfast
White bread, sliced, no crusts 185 1943 a89 78 4 8 15 14
Water, bottled 250 0 0 0 0 0 0 0
Ad lib lunch
Meat sauce, beef & tomato 1385 3858 55 25 39 38 83 37
Pasta, spirals, boiled 960 5662 278 82 6 4 45 13
Water, bottled 250 0 0 0 0 0 0 0
CHO carbohydrate; a83g polysaccharide starch
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advised that they could eat as much or as little as they
chose and to eat until they were comfortably full. The
lunch meal was served in individual booths to ensure
that all participants remained undisturbed during the
meal time, where they were required to remain for a
period of 30 min. Lunch items were weighed both im-
mediately before and after consumption of the meal.
Energy, fat, CHO and protein intake were calculated
using the dietary software program FoodWorks™ (Pro-
fessional Edition, Version 5, 1998–2007, Xyris Software,
Australia).
Statistical analyses
Data on demographic and anthropometric characteris-
tics were summarized using descriptive statistics, and
presented as mean, standard deviation (mean, SD).
Power calculations confirmed a sample size of 20 indi-
viduals to be sufficient to detect a 10 % change in the
primary outcome, VAS hunger/fullness, as statistically
significant in this pair wise, cross-over design. Based on
this sample size, a change in EI at the outcome lunch
meal of ~0.5MJ or greater was expected to also reach
significance. Efficacy endpoints of VAS and EI were
presented as mean, standard error of the mean (mean,
SEM). VAS data assessing feelings of hunger, fullness
and other satiety indicators throughout the study days as
well as VAS data assessing the palatability of the break-
fast and lunch meals were analysed using repeated
measures Linear Mixed Model ANOVA (SAS: PROC
MIXED, SAS version 9.2, SAS Institute Inc, Cary, NC,
USA, 2002–2008). The energy and macronutrient intake
data from the outcome meal following each of the three
supplement arms was also analysed using ANOVA.
Intervention arm, participant and study day were
included in the procedure, in addition to the supple-
ment/time interaction which addressed whether the
trajectory of VAS over time during the study period
differed between the three arms (diet*time). Statistical
significance was set at P < 0.05.
Results
Participants
Twenty male participants were screened, enrolled and
randomised into this cross-over trial. The men were lean
and healthy with a mean age of 26.4 years (1.7, SD) and
a mean BMI of 23.1 kg/m2 (0.7, SD). All 20 participants
completed the three study arms with no drop outs,
exclusions or any lost to follow up. There were no
reports of abdominal discomfort, nausea or other
adverse GI symptoms during the study, indicating that
both low (PGE500) and high (PGE1500) doses were well
tolerated.
VAS-rated appetite perceptions
The mean VAS-rated changes in hunger, fullness, TOF
and satisfaction measured throughout each study day on
each of the three arms are shown in Fig. 2. Fasting base-
line scores for hunger, fullness, TOF and satisfaction did
not differ between the three supplements, confirming
that participants were in a comparable appetitive state at
the start of each study day (all, P > 0.05). As expected,
prior to consumption of the breakfast, scores for hunger
were high and fullness low, a trend observed across all
three arms. Consumption of the breakfast plus PGE or
placebo capsules significantly decreased hunger and
increased fullness scores on all 3 arms compared with
baseline scores (all, P < 0.05). The VAS-rated changes in
satisfaction and TOF were similar and consistent with
those of hunger and fullness (Fig. 2, all, P < 0.05). The
plots show consistent and predictable changes in line
with known physiological effects. However, there was no
significant difference between PGE supplements and
inactive placebo in any of the VAS assessments either
over the 180 min period between breakfast and lunch
or throughout the full study day (time*supplement,
all, P > 0.05), confirming that there was no effect of
either PGE500 or PGE1500 on subjective measures of
appetite compared with the inactive placebo.
VAS-rated palatability and nausea
Participants rated the pleasantness, visual appeal, smell,
taste, aftertaste and overall palatability immediately after
the breakfast and the ad lib lunch meal (data not
shown). In general palatability of the breakfast (white
bread) was low, and palatability of the lunch (pasta and
meat sauce) was high. There was no effect of any of the
three intervention arms on these outcomes, hence no
evidence of adverse sensory effects caused by adminis-
tration of either the low- or high-dose PGE capsules
when compared with inactive placebo. There was also
no evidence of nausea induced by the PGE500 or
PGE1500 capsules.
Energy intake at ad libitum lunch
Ad lib EI at the lunch meal is presented for each study
arm in Fig. 3. Mean (SEM) EI at lunch was 3079 (187)
kJ, 3243 (225) kJ and 3028 (194) kJ for placebo, PGE500
and PGE1500, respectively. EI following PGE500 was
+164 kJ higher than placebo (+5.3 %); and EI following
PGE1500was −51 kJ lower than placebo (−1.7 %). There
was no significant difference between supplements
(ANOVA, P > 0.05), hence no evidence that PGE at
either dose when delivered within a capsule and with a
starch-rich breakfast meal significantly altered EI relative
to placebo.













Fig. 3 Mean (SEM) energy and macronutrient intake at the ad libitum lunch meal for each treatment PGE500, polyphenolic grape extract 500mg;
PGE1500, polyphenolic grape extract 1500mg. CHO, carbohydrate
Fig. 2 Mean (SEM) VAS-rated hunger, fullness, thoughts of food (TOF) and satisfaction throughout the day in response to 3 breakfast treatments:
placebo; low-dose PGE (PGE500, 500 mg); high-dose PGE (PGE1500, 1500 mg). PGE, polyphenolic grape extract
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Discussion
In this study we were interested in determining the
effect that encapsulated PGE, proposed as a rich source
of polyphenols, may have on the ileal brake mechanism
of appetite control. Evidence from naso-ileal tube studies
that delivery of nutrients directly to the distal SI may
impose a brake on appetite has generated considerable
interest [7, 8, 32], and lead to speculation that it may be
possible to induce the ileal brake following a meal. The
hypothesis that orally delivered monosaccharide glucose
may avoid absorption in the duodenum and hence
transit through to the distal SI and thereby enhance
satiety was originally proposed following studies where
pharmaceutical α-glucosidases were administered with a
CHO-rich meal [21, 22]. Prescribed as oral therapeutics
to promote better regulation of blood glucose and
prevent significant postprandial glucose excursions in
patients with impaired glucose tolerance (IGT) or
type 2 diabetes (T2D), the α-glucosidases or’ starch
blockers’ act to decrease the rate of starch digestion
through reversible inhibition of pancreatic α-amylase
and membrane-bound intestinal α-glucosidase [12, 33–35].
They include acarbose, voglibose and miglitol which
essentially induce malabsorption by preventing or slow-
ing the breakdown of complex CHO to glucose in the
proximal SI, moving the absorption site of CHO to the
distal portion of the intestine. In clinical studies where
these starch blockers have been given with a high
CHO-meal, the rate of gastric emptying has decreased
and sustained enhancement of peptides associated with
satiety has been reported, including glucagon-like
peptide-1 (GLP-1) which is secreted predominantly
from the ileal epithelial endocrine L-cells [21, 22, 36, 37].
These trials have also demonstrated suppression of
appetite, albeit with mild to moderate GI adverse
events [21, 22], attributed to malabsorption of CHO
within the proximal SI and increasing concentration of
glucose within the distal SI including the ileum. There-
fore, it is conceivable that dietary sources of naturally
occurring α-glucosidase and α-amylase inhibitors, such
as those of plant-origin including grapes, may also
suppress proximal SI glucose digestion allowing deliv-
ery of glucose distally.
PGE, amongst a number of other naturally occurring
plant extracts rich in bioactive polyphenols, has been
demonstrated in vitro to be a potent inhibitor of the
α-glucosidases [24, 38, 39], but whether it could
modulate appetite and EI had not previously been
investigated. Interestingly, there are some prior animal
studies which have reported a link between PGE and
decreased food intake and body weight, although with
no direct evidence that the effects were driven by
change in appetite regulation. In an early study in rats,
12-week supplementation of grape seed extract (GSE)
decreased food intake and prevented weight gain [40].
Notably, the authors attributed the results in part to a
binding affinity of the polyphenols for specific proteins
within the ingested food, forming aggregates in the GI
tract and leading to delayed digestibility and absorption of
the nutrients. In a more recent study rodents with obesity
induced by a high fat diet were supplemented with GSE
over 5 weeks, and reported prevention of further weight
gain and improvement in obesity-related serum biochem-
istry such as circulating lipid profile [41]. Neither study at-
tributed the effects on body weight to changes in appetite
regulation, despite the changes in food intake. Our study
was the first to assess the efficacy of PGE delivered within
a capsule at the same time as a high starch breakfast meal
and found that whilst PGE at doses of 500 and 1500 mg
was safe and well tolerated, it did not significantly modu-
late appetite or EI when compared to a matched placebo.
There are several important methodological issues to
be noted from our study. Grape extracts are widely
consumed as a nutritional supplement worldwide, are
generally regarded as safe (GRAS) [14, 15, 42] and in
our present study we were able to confirm the tolerabil-
ity of PGE doses ranging from 500 to 1500 mg in healthy
males. Notably, suppression of food intake was observed
in the rodent trials at a dose of between 70 and 100 mg/
kg GSE [40, 41]. Body surface area (BSA) normalisation
algorithms [43], albeit a simple approach to dose con-
version [44], show this to be to a human equivalent
dose (HED) of ~350–1,000 mg in a 60 kg adult (HED,
mg/kg = rodent dose, mg/kg × [rodent Km/human Km],
where mouse Km = 3, rat Km = 6, human Km = 37), and in-
dicate that sufficient dose may have been administered in
our current trial. Secondly, a lack of information on the
absorption and bioavailability of PGE-derived polyphenols
in humans raised a challenge in our current study, where
the intent was to orally deliver sufficient concentration of
polyphenols into the proximal SI in order to delay CHO
absorption. We did not assess this outcome in this trial.
Thirdly, partially blocking starch breakdown may not have
been sufficient to enable distal transit of dietary glucose
which may also require inhibition of glucose uptake as it
passed through the proximal SI.
Conclusions
In our present clinical study, whilst we were able to
confirm the tolerability of PGE doses ranging from 500
to 1500 mg in a group of healthy males, there was no
evidence that supplementation with PGE altered post-
prandial appetite response to a starch-rich breakfast
meal nor ad lib energy or macronutrient intake at a later
lunch meal, relative to a matched placebo. It is not
known whether PGE can delay digestion and absorption
of available CHO and enhance delivery of glucose to the
ileum in a clinical setting. Whether PGE administered at
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different time intervals (pre or post CHO meal), at
higher or repeated doses over a longer time period, or
synergistically with glucose uptake blockers, can alter
satiety is not known and may be of interest for investiga-
tion in future trials.
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